Donald Trump has triggered plans to impose 100% tariffs on some imported pharmaceutical products, citing national security concerns and a desire to boost domestic manufacturing. The proposal would target medicines and raw ingredients sourced largely from countries such as China and India, which currently dominate key segments of the global supply chain.

If a pharmaceutical product is from the European Union, Japan, Korea, or Switzerland and Liechtenstein, a 15% tariff will apply.  If a pharmaceutical product is from the United Kingdom, a lower tariff will apply (10%), subject to the recently concluded UK pharmaceutical agreement.

The tariffs will come into effect in 120 days for certain large companies, and 180 days for smaller companies.

The move is intended to reduce US reliance on foreign drug production and encourage companies to re-shore manufacturing. However, industry experts and healthcare stakeholders have warned that such tariffs could lead to increased drug costs and potential supply disruptions in the short term.

Pharmaceutical companies have expressed concern that shifting production domestically would require significant investment, time, and regulatory adjustments. Analysts note that while the long-term goal of supply chain resilience may be beneficial, immediate impacts could include higher prices for patients and pressure on healthcare systems.

The proposal reflects broader efforts to reassess global trade dependencies in critical sectors, with pharmaceuticals increasingly viewed as strategically important.